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In the original published version of the above article, there were typographical errors in Figure 1A and its corresponding figure legend.
The concentration of ceramide used was micromolar, not millimolar. These errors have now been fixed online and are also shown
here. The authors apologize for any inconvenience caused by this error.A
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Figure 1. Evidence that Ceramide Causes Insulin Resistance in a Cells
(A) In the absence of ceramide, 30 units of insulin cause marked downregulation of glucagon mRNA in cultured a cells. The presence of 50 mM ceramide
completely prevents the downregulation by insulin.
(B) In glucagon receptor knockout (GcgR/) mice, complete deficiency of insulin caused by high dose streptozotocin (STZ) administration does not cause
hyperglycemia or any apparent clinical or metabolic abnormality (days 1–8). However, when adenovirus containing the glucagon receptor cDNA is injected,
causing the glucagon receptormRNA to appear in the liver, blood glucose rises near 500mg/dl. When the transgenic glucagon receptor has disappeared from the
liver (day 15), the hyperglycemia also subsequently disappears. These results show that the metabolic defects of diabetes are not caused directly by lack of
insulin but rather require hyperglucagonemia caused by failure of paracrine insulin to suppress glucagon levels.
(C) Comparison of glucose profiles of insulin-deficient T1D NOD mice treated with ‘‘optimal’’ insulin replacement (0.2 U/day, black squares) or with glucagon
Figures adapted from Lee et al., 2012 and Wang et al., 2010.suppression with continuous infusion of metroleptin (20 mg/hr, open squares).Cell Metabolism 21, 647, April 7, 2015 ª2015 Elsevier Inc. 647
